Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause.
| Autor: | Roberts MZ; Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Huntsville, AL, USA.; Univeristy of Alabama (UAB) - Huntsville Regional Medical Center, Huntsville, AL, USA., Andrus MR; Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Huntsville, AL, USA.; Univeristy of Alabama (UAB) - Huntsville Regional Medical Center, Huntsville, AL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2024 Jun; Vol. 25 (9), pp. 1131-1136. Date of Electronic Publication: 2024 Jul 08. |
| DOI: | 10.1080/14656566.2024.2375039 |
| Abstrakt: | Introduction: During menopause, the majority of women experience vasomotor symptoms which may lead to several untoward effects and negatively impact quality of life. Fezolinetant, a novel agent directly targeting the underlying pathophysiology of menopause-associated vasomotor symptoms, offers an alternative to hormonal therapies for which many patients have a contraindication or unwillingness to take due to safety concerns. Areas Covered: This review summarizes key pharmacologic, pharmacokinetic, and pharmacodynamic parameters of fezolinetant along with efficacy and safety data derived from clinical trials. A literature search of peer-reviewed publications evaluating the efficacy and safety of fezolinetant was conducted using PubMed and EMBASE databases. A review of registered trials in clinicaltrials.gov was evaluated to identify ongoing studies. Expert Opinion: Placebo-controlled studies demonstrated that fezolinetant led to a statistically significant reduction in vasomotor symptom frequency and severity among patients with moderate-to-severe vasomotor symptoms. The most common adverse event is headache (5-10%) and no serious safety signals have been noted. Direct head-to-head comparison with hormonal therapies and nonhormonal therapies for vasomotor symptoms, assessment of sleep outcomes, and evaluation of efficacy and safety beyond 1 year are key areas where additional data are still needed. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|